NR 565 / NR565 ADVANCED PHARMACOLOGY
Midterm Exam Review | Rated A | Latest 2026/2027 | Chamberlain
Comprehensive Midterm Examination Review
Aligned with Chamberlain University NR565 Advanced Pharmacology Course Syllabus, AACN Essentials of Master's Education, and
Advanced Practice Pharmacotherapeutics Standards (2026/2027 Edition)
Total Questions 130 Cognitive Mix 25% Recall • 50% Application • 25% Analysis
Question Style 75% Scenario-based • 25% Direct knowledge
Format Multiple choice (4 options, one correct)
Sections 11 (PK/PD → Drug Interactions) Special Focus 12 CYP450 interactions • 10 monitoring/ADRs • 8 special populatio
[CORRECT] = correct answer marker • Questions span pharmacokinetics through drug interactions and monitoring • Each rationale cites
NR565 curriculum, AACN Essentials, and advanced pharmacology standards.
Section 1: Pharmacokinetics & Pharmacodynamics
15 Questions | Absorption • Distribution • Metabolism (CYP450) • Excretion • Half-life • Bioavailability • First-pass effect • Receptor theory •
Agonists/antagonists • Dose-response curves • Therapeutic index • Potency vs. efficacy • First vs. zero-order kinetics • Vd • Loading dose
Q1: A patient receiving oral morphine for chronic cancer pain experiences inadequate
analgesia despite dose escalation. Considering first-pass metabolism, which route would
MOST improve bioavailability?
A. Sublingual administration
B. Intravenous (IV) administration bypasses hepatic first-pass metabolism, achieving 100% bioavailability
[CORRECT]
C. Increasing oral dose further
D. Adding an antiemetic
Correct Answer: B
Rationale: IV administration bypasses hepatic first-pass metabolism, providing 100% bioavailability (F = 1.0).
Sublingual (A) reduces first-pass but variably; increasing oral dose (C) is limited by first-pass saturation and side effects.
NR565 emphasizes bioavailability and first-pass effects for route selection.
Q2: Which CYP450 enzyme isozyme is responsible for metabolizing approximately 25% of all
clinically used drugs, including many beta-blockers, antidepressants, and antipsychotics?
A. CYP3A4
B. CYP2D6 [CORRECT]
C. CYP2C9
D. CYP1A2
Correct Answer: B
Rationale: CYP2D6 metabolizes ~25% of clinically used drugs, including beta-blockers (metoprolol), antidepressants
(fluoxetine, paroxetine), antipsychotics (risperidone), and codeine (bioactivation to morphine). CYP3A4 (A) metabolizes
~50% but is different. NR565 requires knowledge of major CYP450 isozymes for predicting drug interactions.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 1
,NR 565 ADVANCED PHARMACOLOGY | MIDTERM EXAM REVIEW | CHAMBERLAIN
Q3: A drug has a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A. 12 hours
B. 24 hours
C. Approximately 60 hours (5 half-lives: 5 × 12 = 60 hours) [CORRECT]
D. 120 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 5 half-lives of repeated dosing. For a drug with t½ = 12 hours,
steady state takes ~60 hours (2.5 days). NR565 pharmacokinetics requires calculating time to steady state for dosing
decisions. A loading dose may be used when rapid steady state is needed.
Q4: A patient on warfarin (CYP2C9 substrate) is started on fluconazole, a potent CYP2C9
inhibitor. What effect is anticipated on warfarin's therapeutic effect?
A. Decreased INR (warfarin effect reduced)
B. Increased INR and bleeding risk (warfarin effect enhanced by reduced clearance) [CORRECT]
C. No change
D. Immediate need for higher warfarin dose
Correct Answer: B
Rationale: CYP2C9 inhibition by fluconazole reduces warfarin clearance, increasing plasma warfarin levels and INR,
raising bleeding risk. NR565 requires recognition of CYP450 drug interactions and dose adjustment. The warfarin dose
should be reduced or the combination avoided with close INR monitoring.
Q5: Which pharmacodynamic concept describes the maximum effect a drug can produce,
regardless of dose increases?
A. Potency
B. Efficacy (Emax) [CORRECT]
C. Affinity
D. Therapeutic index
Correct Answer: B
Rationale: Efficacy (Emax) is the maximum effect a drug can produce, while potency refers to the dose required to
produce a given effect (EC50). A drug can have high potency but low efficacy (e.g., partial agonists). NR565 requires
distinguishing potency from efficacy for drug selection.
Q6: A drug with a narrow therapeutic index requires careful monitoring. Which parameter
defines the therapeutic index?
A. LD50/ED50 ratio [CORRECT]
B. Time to peak concentration
C. Half-life
D. Bioavailability
Correct Answer: A
Rationale: Therapeutic Index (TI) = LD50/ED50 (lethal dose in 50% / effective dose in 50%). A narrow TI (e.g.,
warfarin, digoxin, lithium) requires therapeutic drug monitoring. NR565 requires identifying narrow-TI drugs and
monitoring parameters.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 2
,NR 565 ADVANCED PHARMACOLOGY | MIDTERM EXAM REVIEW | CHAMBERLAIN
Q7: A drug is a partial agonist at receptor B. Compared to a full agonist, the partial agonist will:
A. Always produce a stronger maximal effect
B. Produce a submaximal effect even at full receptor occupancy, and can act as an antagonist in the
presence of a full agonist [CORRECT]
C. Have no effect at all
D. Bind irreversibly to the receptor
Correct Answer: B
Rationale: Partial agonists produce submaximal response (low intrinsic efficacy) even at full receptor occupancy, and in
the presence of a full agonist, they act as competitive antagonists (e.g., buprenorphine at mu-opioid receptors). NR565
pharmacodynamics requires distinguishing full agonists, partial agonists, antagonists.
Q8: A patient with cirrhosis requires a medication normally metabolized hepatically. Which
pharmacokinetic parameter is MOST affected?
A. Absorption
B. Distribution (altered protein binding from reduced albumin)
C. Metabolism (reduced clearance, prolonged half-life) [CORRECT]
D. Renal excretion
Correct Answer: C
Rationale: Hepatic dysfunction reduces drug metabolism, decreasing clearance and prolonging half-life. Additionally,
hypoalbuminemia (common in cirrhosis) increases free fraction of highly protein-bound drugs. NR565 requires dose
adjustment for hepatic impairment based on Child-Pugh class.
Q9: Which of the following is the PRIMARY mechanism by which grapefruit juice interacts with
medications?
A. Induction of CYP3A4 in the liver
B. Irreversible inhibition of intestinal CYP3A4, increasing bioavailability of orally administered CYP3A4
substrates (e.g., statins, CCBs) [CORRECT]
C. Increased gastric pH
D. Reduced gastric emptying
Correct Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4 (not hepatic), increasing bioavailability of oral
CYP3A4 substrates such as simvastatin, atorvastatin, felodipine. The effect persists 24–72 hours. NR565 requires
recognition of food-drug interactions via CYP3A4.
Q10: Drug A has an ED50 of 5 mg; Drug B has an ED50 of 50 mg. Which statement is correct?
A. Drug A is more efficacious
B. Drug B is more potent
C. Drug A is more potent (lower dose required for 50% effect) [CORRECT]
D. Both drugs have equal potency
Correct Answer: C
Rationale: Potency is inversely related to ED50 (lower ED50 = higher potency). Drug A's ED50 (5 mg) is lower than
Drug B's (50 mg), so Drug A is more potent. Potency does NOT indicate efficacy—both could have similar Emax.
NR565 pharmacodynamics requires distinguishing potency from efficacy.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 3
, NR 565 ADVANCED PHARMACOLOGY | MIDTERM EXAM REVIEW | CHAMBERLAIN
Q11: A patient with severe renal impairment (eGFR 18 mL/min/1.73m²) is prescribed
gentamicin. Which pharmacokinetic change is MOST critical?
A. Increased absorption
B. Reduced renal excretion, requiring dose reduction and monitoring of peak/trough levels to prevent
nephrotoxicity and ototoxicity [CORRECT]
C. Increased hepatic metabolism
D. Increased protein binding
Correct Answer: B
Rationale: Renal impairment reduces aminoglycoside excretion, requiring dose reduction and interval extension with
peak/trough monitoring. Gentamicin has narrow TI; risk of nephrotoxicity and ototoxicity increases. NR565 requires dose
adjustment for renally cleared drugs based on eGFR.
Q12: Which of the following describes the volume of distribution (Vd)?
A. The total drug dose administered
B. Theoretical volume that would be required to contain the total absorbed drug at the plasma
concentration [CORRECT]
C. The rate of drug clearance
D. The drug's half-life
Correct Answer: B
Rationale: Vd = Dose / Plasma concentration. High Vd indicates extensive tissue distribution (e.g., lipophilic drugs); low
Vd indicates confinement to plasma (e.g., hydrophilic, highly protein-bound drugs). NR565 uses Vd for loading dose
calculation.
Q13: A patient is a CYP2C19 poor metabolizer and is prescribed clopidogrel. What is the
anticipated clinical effect?
A. Increased antiplatelet effect
B. Reduced activation of clopidogrel to its active metabolite, resulting in diminished antiplatelet effect and
increased thrombotic risk [CORRECT]
C. No change
D. Immediate bleeding
Correct Answer: B
Rationale: Clopidogrel is a prodrug activated by CYP2C19. Poor metabolizers (e.g., *2/*2 or *3/*3 alleles) have reduced
clopidogrel activation, leading to diminished antiplatelet effect and increased thrombotic risk. NR565 requires
pharmacogenomic considerations for drug selection—consider alternative (prasugrel, ticagrelor).
Q14: Which of the following is an example of a pharmacodynamic drug interaction?
A. Cimetidine inhibiting CYP1A2, increasing theophylline levels
B. Aspirin and warfarin both inhibiting clotting via different mechanisms, increasing bleeding risk
[CORRECT]
C. Grapefruit juice inhibiting intestinal CYP3A4
D. Antacids reducing absorption of fluoroquinolones
Correct Answer: B
Rationale: Pharmacodynamic interactions involve additive, synergistic, or antagonistic effects at the same or different
receptor sites (e.g., aspirin + warfarin both inhibit clotting). Options A, C, D are pharmacokinetic interactions (altered
absorption, metabolism, distribution). NR565 requires distinguishing PK vs PD interactions.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 4
Midterm Exam Review | Rated A | Latest 2026/2027 | Chamberlain
Comprehensive Midterm Examination Review
Aligned with Chamberlain University NR565 Advanced Pharmacology Course Syllabus, AACN Essentials of Master's Education, and
Advanced Practice Pharmacotherapeutics Standards (2026/2027 Edition)
Total Questions 130 Cognitive Mix 25% Recall • 50% Application • 25% Analysis
Question Style 75% Scenario-based • 25% Direct knowledge
Format Multiple choice (4 options, one correct)
Sections 11 (PK/PD → Drug Interactions) Special Focus 12 CYP450 interactions • 10 monitoring/ADRs • 8 special populatio
[CORRECT] = correct answer marker • Questions span pharmacokinetics through drug interactions and monitoring • Each rationale cites
NR565 curriculum, AACN Essentials, and advanced pharmacology standards.
Section 1: Pharmacokinetics & Pharmacodynamics
15 Questions | Absorption • Distribution • Metabolism (CYP450) • Excretion • Half-life • Bioavailability • First-pass effect • Receptor theory •
Agonists/antagonists • Dose-response curves • Therapeutic index • Potency vs. efficacy • First vs. zero-order kinetics • Vd • Loading dose
Q1: A patient receiving oral morphine for chronic cancer pain experiences inadequate
analgesia despite dose escalation. Considering first-pass metabolism, which route would
MOST improve bioavailability?
A. Sublingual administration
B. Intravenous (IV) administration bypasses hepatic first-pass metabolism, achieving 100% bioavailability
[CORRECT]
C. Increasing oral dose further
D. Adding an antiemetic
Correct Answer: B
Rationale: IV administration bypasses hepatic first-pass metabolism, providing 100% bioavailability (F = 1.0).
Sublingual (A) reduces first-pass but variably; increasing oral dose (C) is limited by first-pass saturation and side effects.
NR565 emphasizes bioavailability and first-pass effects for route selection.
Q2: Which CYP450 enzyme isozyme is responsible for metabolizing approximately 25% of all
clinically used drugs, including many beta-blockers, antidepressants, and antipsychotics?
A. CYP3A4
B. CYP2D6 [CORRECT]
C. CYP2C9
D. CYP1A2
Correct Answer: B
Rationale: CYP2D6 metabolizes ~25% of clinically used drugs, including beta-blockers (metoprolol), antidepressants
(fluoxetine, paroxetine), antipsychotics (risperidone), and codeine (bioactivation to morphine). CYP3A4 (A) metabolizes
~50% but is different. NR565 requires knowledge of major CYP450 isozymes for predicting drug interactions.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 1
,NR 565 ADVANCED PHARMACOLOGY | MIDTERM EXAM REVIEW | CHAMBERLAIN
Q3: A drug has a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A. 12 hours
B. 24 hours
C. Approximately 60 hours (5 half-lives: 5 × 12 = 60 hours) [CORRECT]
D. 120 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 5 half-lives of repeated dosing. For a drug with t½ = 12 hours,
steady state takes ~60 hours (2.5 days). NR565 pharmacokinetics requires calculating time to steady state for dosing
decisions. A loading dose may be used when rapid steady state is needed.
Q4: A patient on warfarin (CYP2C9 substrate) is started on fluconazole, a potent CYP2C9
inhibitor. What effect is anticipated on warfarin's therapeutic effect?
A. Decreased INR (warfarin effect reduced)
B. Increased INR and bleeding risk (warfarin effect enhanced by reduced clearance) [CORRECT]
C. No change
D. Immediate need for higher warfarin dose
Correct Answer: B
Rationale: CYP2C9 inhibition by fluconazole reduces warfarin clearance, increasing plasma warfarin levels and INR,
raising bleeding risk. NR565 requires recognition of CYP450 drug interactions and dose adjustment. The warfarin dose
should be reduced or the combination avoided with close INR monitoring.
Q5: Which pharmacodynamic concept describes the maximum effect a drug can produce,
regardless of dose increases?
A. Potency
B. Efficacy (Emax) [CORRECT]
C. Affinity
D. Therapeutic index
Correct Answer: B
Rationale: Efficacy (Emax) is the maximum effect a drug can produce, while potency refers to the dose required to
produce a given effect (EC50). A drug can have high potency but low efficacy (e.g., partial agonists). NR565 requires
distinguishing potency from efficacy for drug selection.
Q6: A drug with a narrow therapeutic index requires careful monitoring. Which parameter
defines the therapeutic index?
A. LD50/ED50 ratio [CORRECT]
B. Time to peak concentration
C. Half-life
D. Bioavailability
Correct Answer: A
Rationale: Therapeutic Index (TI) = LD50/ED50 (lethal dose in 50% / effective dose in 50%). A narrow TI (e.g.,
warfarin, digoxin, lithium) requires therapeutic drug monitoring. NR565 requires identifying narrow-TI drugs and
monitoring parameters.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 2
,NR 565 ADVANCED PHARMACOLOGY | MIDTERM EXAM REVIEW | CHAMBERLAIN
Q7: A drug is a partial agonist at receptor B. Compared to a full agonist, the partial agonist will:
A. Always produce a stronger maximal effect
B. Produce a submaximal effect even at full receptor occupancy, and can act as an antagonist in the
presence of a full agonist [CORRECT]
C. Have no effect at all
D. Bind irreversibly to the receptor
Correct Answer: B
Rationale: Partial agonists produce submaximal response (low intrinsic efficacy) even at full receptor occupancy, and in
the presence of a full agonist, they act as competitive antagonists (e.g., buprenorphine at mu-opioid receptors). NR565
pharmacodynamics requires distinguishing full agonists, partial agonists, antagonists.
Q8: A patient with cirrhosis requires a medication normally metabolized hepatically. Which
pharmacokinetic parameter is MOST affected?
A. Absorption
B. Distribution (altered protein binding from reduced albumin)
C. Metabolism (reduced clearance, prolonged half-life) [CORRECT]
D. Renal excretion
Correct Answer: C
Rationale: Hepatic dysfunction reduces drug metabolism, decreasing clearance and prolonging half-life. Additionally,
hypoalbuminemia (common in cirrhosis) increases free fraction of highly protein-bound drugs. NR565 requires dose
adjustment for hepatic impairment based on Child-Pugh class.
Q9: Which of the following is the PRIMARY mechanism by which grapefruit juice interacts with
medications?
A. Induction of CYP3A4 in the liver
B. Irreversible inhibition of intestinal CYP3A4, increasing bioavailability of orally administered CYP3A4
substrates (e.g., statins, CCBs) [CORRECT]
C. Increased gastric pH
D. Reduced gastric emptying
Correct Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4 (not hepatic), increasing bioavailability of oral
CYP3A4 substrates such as simvastatin, atorvastatin, felodipine. The effect persists 24–72 hours. NR565 requires
recognition of food-drug interactions via CYP3A4.
Q10: Drug A has an ED50 of 5 mg; Drug B has an ED50 of 50 mg. Which statement is correct?
A. Drug A is more efficacious
B. Drug B is more potent
C. Drug A is more potent (lower dose required for 50% effect) [CORRECT]
D. Both drugs have equal potency
Correct Answer: C
Rationale: Potency is inversely related to ED50 (lower ED50 = higher potency). Drug A's ED50 (5 mg) is lower than
Drug B's (50 mg), so Drug A is more potent. Potency does NOT indicate efficacy—both could have similar Emax.
NR565 pharmacodynamics requires distinguishing potency from efficacy.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 3
, NR 565 ADVANCED PHARMACOLOGY | MIDTERM EXAM REVIEW | CHAMBERLAIN
Q11: A patient with severe renal impairment (eGFR 18 mL/min/1.73m²) is prescribed
gentamicin. Which pharmacokinetic change is MOST critical?
A. Increased absorption
B. Reduced renal excretion, requiring dose reduction and monitoring of peak/trough levels to prevent
nephrotoxicity and ototoxicity [CORRECT]
C. Increased hepatic metabolism
D. Increased protein binding
Correct Answer: B
Rationale: Renal impairment reduces aminoglycoside excretion, requiring dose reduction and interval extension with
peak/trough monitoring. Gentamicin has narrow TI; risk of nephrotoxicity and ototoxicity increases. NR565 requires dose
adjustment for renally cleared drugs based on eGFR.
Q12: Which of the following describes the volume of distribution (Vd)?
A. The total drug dose administered
B. Theoretical volume that would be required to contain the total absorbed drug at the plasma
concentration [CORRECT]
C. The rate of drug clearance
D. The drug's half-life
Correct Answer: B
Rationale: Vd = Dose / Plasma concentration. High Vd indicates extensive tissue distribution (e.g., lipophilic drugs); low
Vd indicates confinement to plasma (e.g., hydrophilic, highly protein-bound drugs). NR565 uses Vd for loading dose
calculation.
Q13: A patient is a CYP2C19 poor metabolizer and is prescribed clopidogrel. What is the
anticipated clinical effect?
A. Increased antiplatelet effect
B. Reduced activation of clopidogrel to its active metabolite, resulting in diminished antiplatelet effect and
increased thrombotic risk [CORRECT]
C. No change
D. Immediate bleeding
Correct Answer: B
Rationale: Clopidogrel is a prodrug activated by CYP2C19. Poor metabolizers (e.g., *2/*2 or *3/*3 alleles) have reduced
clopidogrel activation, leading to diminished antiplatelet effect and increased thrombotic risk. NR565 requires
pharmacogenomic considerations for drug selection—consider alternative (prasugrel, ticagrelor).
Q14: Which of the following is an example of a pharmacodynamic drug interaction?
A. Cimetidine inhibiting CYP1A2, increasing theophylline levels
B. Aspirin and warfarin both inhibiting clotting via different mechanisms, increasing bleeding risk
[CORRECT]
C. Grapefruit juice inhibiting intestinal CYP3A4
D. Antacids reducing absorption of fluoroquinolones
Correct Answer: B
Rationale: Pharmacodynamic interactions involve additive, synergistic, or antagonistic effects at the same or different
receptor sites (e.g., aspirin + warfarin both inhibit clotting). Options A, C, D are pharmacokinetic interactions (altered
absorption, metabolism, distribution). NR565 requires distinguishing PK vs PD interactions.
NR 565 Advanced Pharmacology Midterm Review | Rated A | 2026/2027 Page 4
